<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DISEASE CHARACTERISTICS: Diamond-Blackfan <z:hpo ids='HP_0001903'>anemia</z:hpo> (<z:chebi fb="28" ids="35299">DBA</z:chebi>) in its classic form is characterized by a profound isolated normochromic and usually <z:hpo ids='HP_0001972'>macrocytic anemia</z:hpo> with <z:mpath ids='MPATH_458'>normal</z:mpath> leukocytes and platelets, <z:e sem="disease" ids="C1705254" disease_type="Disease or Syndrome" abbrv="">congenital malformations</z:e> in approximately 50% of affected individuals, and <z:hpo ids='HP_0001510'>growth retardation</z:hpo> in 30% of affected individuals </plain></SENT>
<SENT sid="1" pm="."><plain>The hematologic complications occur in 90% of affected individuals during the first year of life (median <z:hpo ids='HP_0011007'>age of onset</z:hpo> is two months) </plain></SENT>
<SENT sid="2" pm="."><plain>Eventually, 40% of affected individuals are <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> dependent, 40% are transfusion dependent, and 20% go into remission </plain></SENT>
<SENT sid="3" pm="."><plain>The phenotypic spectrum ranges from a mild form (e.g., mild <z:hpo ids='HP_0001903'>anemia</z:hpo>; no <z:hpo ids='HP_0001903'>anemia</z:hpo> with only subtle erythroid abnormalities; physical malformations without <z:hpo ids='HP_0001903'>anemia</z:hpo>) to a severe form of fetal <z:hpo ids='HP_0001903'>anemia</z:hpo> resulting in non-immune <z:hpo ids='HP_0001789'>hydrops fetalis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="28" ids="35299">DBA</z:chebi> is associated with an increased risk of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> including <z:hpo ids='HP_0002669'>osteogenic sarcoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>DIAGNOSIS/TESTING: The diagnosis is based on the presence of: normochromic, usually macrocytic, <z:hpo ids='HP_0001903'>anemia</z:hpo>; <z:hpo ids='HP_0001896'>reticulocytopenia</z:hpo>; <z:mpath ids='MPATH_458'>normal</z:mpath> or slightly <z:mp ids='MP_0000221'>decreased leukocyte counts</z:mp>; <z:mpath ids='MPATH_458'>normal</z:mpath> or <z:hpo ids='HP_0001894'>increased platelet counts</z:hpo>; and normocellular bone marrow with selective deficiency of red cell precursors </plain></SENT>
<SENT sid="6" pm="."><plain>Other genetic forms of <z:hpo ids='HP_0001903'>anemia</z:hpo>, such as Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo>, need to be considered and ruled out as appropriate </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="28" ids="35299">DBA</z:chebi> has been associated with mutations in nine genes that encode ribosomal proteins </plain></SENT>
<SENT sid="8" pm="."><plain>A mutation in one of these nine genes is identified in approximately 53% of individuals with <z:chebi fb="28" ids="35299">DBA</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Such testing is available clinically </plain></SENT>
<SENT sid="10" pm="."><plain>MANAGEMENT: Treatment of manifestations: <z:chebi fb="0" ids="50858">Corticosteroid</z:chebi> treatment, recommended in children over age twelve months, can initially improve the red blood count in approximately 80% of affected individuals </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> transfusion with packed red blood cells is initially necessary while the diagnosis is made and in those not responsive to <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>Hematopoietic stem cell transplantation (HSCT), the only curative therapy for the hematologic manifestations of <z:chebi fb="28" ids="35299">DBA</z:chebi>, is often recommended for those who are transfusion-dependent or develop other cytopenias </plain></SENT>
<SENT sid="13" pm="."><plain>Treatment of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> should be coordinated by an oncologist </plain></SENT>
<SENT sid="14" pm="."><plain>Chemotherapy must be given cautiously as it may lead to prolonged cytopenia and subsequent toxicities </plain></SENT>
<SENT sid="15" pm="."><plain>Prevention of secondary complications: Transfusion-related <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> is the most common complication in transfusion-dependent individuals </plain></SENT>
<SENT sid="16" pm="."><plain>Iron chelation therapy with <z:chebi fb="0" ids="49005">deferasirox</z:chebi> orally or <z:chebi fb="0" ids="4356">desferrioxamine</z:chebi> subcutaneously is recommended after 10-20 transfusions </plain></SENT>
<SENT sid="17" pm="."><plain>Steroid-related side effects must also be closely monitored, especially as related to risk of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, <z:hpo ids='HP_0001510'>growth retardation</z:hpo>, and bone density in growing children </plain></SENT>
<SENT sid="18" pm="."><plain>Often patients will be placed on transfusion therapy if these side effects are intolerable </plain></SENT>
<SENT sid="19" pm="."><plain>Surveillance: complete blood counts several times a year; bone marrow aspirate/biopsy to evaluate <z:mp ids='MP_0000002'>morphology</z:mp> and cellularity in the event of another cytopenia or a change in response to treatment </plain></SENT>
<SENT sid="20" pm="."><plain>In steroid-dependent individuals: monitor blood pressure and growth (in children) </plain></SENT>
<SENT sid="21" pm="."><plain>Agents/circumstances to avoid: <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (especially those on <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>); deferiprone for the treatment of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> has lead to severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in a few individuals with <z:chebi fb="28" ids="35299">DBA</z:chebi> </plain></SENT>
<SENT sid="22" pm="."><plain>Testing of relatives at risk: Molecular genetic testing of at-risk relatives of a proband with a known pathogenic mutation allows for early diagnosis and appropriate monitoring for <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo>, physical abnormalities, and related <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="23" pm="."><plain>GENETIC COUNSELING: <z:chebi fb="28" ids="35299">DBA</z:chebi> is inherited in an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> manner </plain></SENT>
<SENT sid="24" pm="."><plain>Approximately 40% to 45% of affected individuals have inherited the mutation from a parent; approximately 55% to 60% have a de novo mutation </plain></SENT>
<SENT sid="25" pm="."><plain>Each child of an individual with <z:chebi fb="28" ids="35299">DBA</z:chebi> has a 50% chance of inheriting the mutation </plain></SENT>
<SENT sid="26" pm="."><plain>Prenatal diagnosis for pregnancies at increased risk is possible if the disease-causing mutation has been identified in the family; if no laboratory offering prenatal testing is listed in the GeneTests Laboratory Directory, such testing may be available through laboratories offering custom mutation prenatal testing </plain></SENT>
</text></document>